Bio

Nathan Cali has more than nine years of combined healthcare, biotechnology and pharmaceutical experience. Mr. Cali's publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics ), medical devices, and regenerative medicine. He has been quoted in most business journals including Reuters, BioMedReports and the Washington Business Journal. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining Noble Financial, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 86, and 87 FINRA designations.